

NOVERIS ANNOUNCES CONVERSION OF DEBENTURES; FILING OF EARLY WARNING REPORTs BY JJK HOLDINGS LTD. AND JOSHUA BARTCH

Vancouver, British Columbia, March 6, 2026 — Noveris Health Sciences Inc. (the “**Company**”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today the conversion of debentures in the aggregate principal amount of \$8,188,628 (the “**Debentures**”) resulting in the issuance of a total of 47,687,939 common shares of the Company, initiated at the option of the debenture holders. The Debentures were originally issued by the Company on October 14, 2025.

Based on their terms and conditions, the Debentures converted at a conversion price of \$0.192682432, being the 20-day trailing volume-weighted average trading price of the Company’s common shares as of the conversion date.

As previously announced on February 27, 2026, JJK Holdings Ltd. (“**JJK**”) acquired a Debenture in the principal amount of \$7,878,792 from its original holder, Pioneer Garage Limited (the “**JJK Debenture**”). The full amount of the JJK Debenture has been converted into 40,890,039 common shares of the Company, and immediately prior to its conversion, was transferred to 23 parties (the “**Transferees**”), all of whom are arm’s length to JJK, except a wholly owned subsidiary of JJK. Upon conversion of all of the Debentures, none of the Transferees holds 10% or greater of the Company’s issued and outstanding shares.

Joshua Bartch, the chief executive officer and a director of the Company, also converted the full amount of his Debenture in the principal amount of \$1,309,836 (the “**Bartch Debenture**”), resulting in the issuance to him of 6,797,900 common shares.

Early Warnings Pursuant to National Instrument 62-103

Prior to the conversion of the Debentures, the Company had 1,235,061 common shares issued and outstanding. As previously disclosed pursuant to JJK’s early warning report disclosure, assuming a conversion price of \$0.185 per share (which was assumed for illustrative purposes only, it having been noted that the actual conversion price may differ), conversion of the JJK Debenture could have resulted in the issuance of 42,588,065 common shares to JJK, representing 97.18% of the Company’s issued and outstanding shares (assuming only the conversion of the JJK Debenture). Upon conversion of all Debentures at the actual conversion price of \$0.192682432 (and following the transfer of the JJK Debenture to the Transferees), JJK, through its wholly owned subsidiary, holds 3,848,706 common shares of the Company, representing 7.86% of its issued and outstanding common shares.

JJK acquired the common shares of the Company (upon conversion of the JJK Debenture) for investment purposes. JJK may, from time to time, acquire additional securities of the Company for investment purposes and may, from time to time, increase or decrease its

beneficial ownership or control of securities of the Company depending on market or other conditions, general economic conditions, the Company's business and financial condition and other factors.

Prior to the conversion of the Debentures, Mr. Bartch held 29,519 common shares of the Company, and the Bartch Debenture. As previously disclosed pursuant to Mr. Bartch's early warning report disclosure, assuming a conversion price of \$0.185 per share (which was assumed for illustrative purposes only, it having been noted that the actual conversion price may differ), conversion of the Bartch Debenture could have resulted in the issuance of 7,080,195 common shares to Mr. Bartch, representing 85.15% of the Company's issued and outstanding shares (assuming only the conversion of the Bartch Debenture). Upon conversion of all Debentures at the actual conversion price of \$0.192682432, Mr. Bartch now holds 6,827,419 common shares of the Company, representing 13.95% of its issued and outstanding common shares.

Mr. Bartch acquired the common shares of the Company (upon conversion of the Bartch Debenture) for investment purposes. Mr. Bartch may, from time to time, acquire additional securities of the Company for investment purposes and may, from time to time, increase or decrease its beneficial ownership or control of securities of the Company depending on market or other conditions, general economic conditions, the Company's business and financial condition and other factors

This news release is being issued as required by National Instrument 62-103 – *The Early Warning System and Related Take-Over Bid and Insider Reporting Issues* and National Instrument 62-104 – *Take-Over Bids and Issuer Bids* and relates to JJK (which has its head office located at 104 Church Street, Sandysport, Nassau, Bahamas, P.O. Box SP-62707), and Mr. Bartch (an individual residing in San Juan, Puerto Rico). A copy of the Early Warning Reports, with additional information in respect of the foregoing matters, will be available under the Company's profile on the SEDAR+ website at www.sedarplus.ca, or by contacting the Company.

For further information or to obtain a copy of the Early Warning Reports of JJK or Mr. Bartch, please contact:

NOVERIS HEALTH SCIENCES INC.

Joshua Bartch
Chief Executive Officer
Email: bartchjosh@gmail.com
Phone: +1 (888) 871 - 3936

About Noveris Health Sciences Inc.

The Company is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Noveris' dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the Company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Noveris' approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with worldclass scientific and regulatory expertise.

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.